INT103155

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 2002
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 78
Total Number 78
Disease Relevance 50.53
Pain Relevance 4.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) plasma membrane (KDR)
nucleus (KDR) cytoplasm (KDR)
Anatomy Link Frequency
bone marrow 10
endothelial cells 6
megakaryocytes 2
endothelium 2
plasma 1
KDR (Homo sapiens)
KDR - V297I (1)
Pain Link Frequency Relevance Heat
metalloproteinase 123 99.36 Very High Very High Very High
cytokine 126 98.82 Very High Very High Very High
agonist 192 98.40 Very High Very High Very High
Inflammation 341 96.52 Very High Very High Very High
headache 24 95.76 Very High Very High Very High
dexamethasone 199 95.72 Very High Very High Very High
Pain 29 95.36 Very High Very High Very High
antagonist 50 94.96 High High
rheumatoid arthritis 8 94.88 High High
COX2 2 94.08 High High
Disease Link Frequency Relevance Heat
Ectopic Pregnancy 95 99.96 Very High Very High Very High
Pancreatic Cancer 277 99.86 Very High Very High Very High
Lymphatic System Cancer 544 99.84 Very High Very High Very High
Myeloproliferative Disorder 229 99.84 Very High Very High Very High
Cholangiocarcinoma 151 99.84 Very High Very High Very High
Cancer 1714 99.78 Very High Very High Very High
Fibromyalgia 22 99.60 Very High Very High Very High
Hyperoxia 15 99.58 Very High Very High Very High
Myeloid Leukemia 347 99.56 Very High Very High Very High
Inflammatory Breast Neoplasms 141 99.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CD34+, or CD45brightCD34+ cells were quantified for KDR expression.
Gene_expression (expression) of KDR
1) Confidence 0.66 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2972200 Disease Relevance 0.15 Pain Relevance 0
The best characterized family member is VEGF-A, the action of which is mediated by its receptors VEGFR-1/Flt-1 and VEGFR-2/KDR/Flk-1 present in endothelial cells (Carmeliet and Collen 1999; Neufeld et al 1999).
Gene_expression (present) of Flk-1 in endothelial cells
2) Confidence 0.65 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676804 Disease Relevance 0.15 Pain Relevance 0.03
The best characterized family member is VEGF-A, the action of which is mediated by its receptors VEGFR-1/Flt-1 and VEGFR-2/KDR/Flk-1 present in endothelial cells (Carmeliet and Collen 1999; Neufeld et al 1999).
Gene_expression (present) of KDR in endothelial cells
3) Confidence 0.65 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676804 Disease Relevance 0.15 Pain Relevance 0.03
HEK293 s cells that were transfected with VEGFR2 V297I SNP had significantly low VEGF binding efficiency regardless of VEGFR2 H472Q genotype, while variant VEGFR2 H472Q allele had minimal effect on VEGF binding efficiency [10].
Gene_expression (transfected) of VEGFR2 (V297I)
4) Confidence 0.65 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2913951 Disease Relevance 0.55 Pain Relevance 0
Apparently, this growth factor is expressed in many other leukemic cell lines [7,26] and a subset of leukemic cells also expresses VEGFR-2 which allows VEGF to act as autocrine growth factor in leukemia [26,27].
Gene_expression (expresses) of VEGFR associated with leukemia
5) Confidence 0.64 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.26 Pain Relevance 0.04
VEGFR-1 is also expressed on hematopoietic stem cells, vascular smooth muscle cells, monocytes, and leukemic cells [6,7], while VEGFR-2 is expressed on endothelial progenitor cells and megakaryocytes [8,9].
Gene_expression (expressed) of VEGFR in megakaryocytes
6) Confidence 0.64 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.28 Pain Relevance 0
VEGFR-1 is also expressed on hematopoietic stem cells, vascular smooth muscle cells, monocytes, and leukemic cells [6,7], while VEGFR-2 is expressed on endothelial progenitor cells and megakaryocytes [8,9].
Gene_expression (expressed) of VEGFR in megakaryocytes
7) Confidence 0.64 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.34 Pain Relevance 0
As biomarkers, VEGF RNA expression by leukemic blasts, bone marrow MVD, and the expression of the target receptors c-kit, Flt3, VEGFR-1, and VEGFR-2 prior to therapy was determined.
Gene_expression (expression) of VEGFR in bone marrow
8) Confidence 0.64 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.97 Pain Relevance 0.22
As biomarkers, VEGF RNA expression by leukemic blasts, bone marrow MVD, and the expression of the target receptors c-kit, Flt3, VEGFR-1, and VEGFR-2 prior to therapy was determined.
Gene_expression (expression) of VEGFR in bone marrow
9) Confidence 0.64 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.97 Pain Relevance 0.22
These results underscore the findings of Itakura et al that some pancreatic cancer cells express such low VEGFR levels that they do not exhibit significant ligand-receptor interactions [82].
Gene_expression (express) of VEGFR associated with pancreatic cancer
10) Confidence 0.60 Published 2003 Journal Mol Cancer Section Body Doc Link PMC150383 Disease Relevance 1.02 Pain Relevance 0.04
The strong association of HIFalphas with the expression of VEGF and pVEGFR2/KDR found in the study provide strong evidence on the role of HIFalphas in the activation of angiogenic and VEGF-autocrine pathways that may be critical therapeutic targets for HIF inhibitors or other antiangiogenic agents [14].


Gene_expression (expression) of KDR
11) Confidence 0.58 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 1.38 Pain Relevance 0
In an attempt to characterize factors affecting production and secretion of VEGF in EP, expression of VEGF mRNA and the VEGF receptors KDR and flt-1 were measured in implanted and non-implanted sites of the oviduct in women with EP41.
Gene_expression (expression) of KDR in oviduct associated with ectopic pregnancy
12) Confidence 0.58 Published 2008 Journal Clinics Section Body Doc Link PMC2664731 Disease Relevance 0.89 Pain Relevance 0.05
A significantly higher expression of HIF1alpha, VEGF, and pVEGFR2/KDR) was recorded in DLBCL compared to follicular lymphomas (FL).
Gene_expression (expression) of KDR associated with diffuse large b-cell lymphoma and follicular lymphoma
13) Confidence 0.58 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 1.51 Pain Relevance 0
Only CD45dimCD34+KDR+ correlated inversely with the number of diseased coronaries (r?
Gene_expression (correlated) of KDR
14) Confidence 0.58 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2972200 Disease Relevance 0.88 Pain Relevance 0
The ISHAGE sequential strategy was used, and finally, CD45dimCD34+ cells were quantified for KDR.
Gene_expression (quantified) of KDR
15) Confidence 0.58 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2972200 Disease Relevance 0.90 Pain Relevance 0
EPC phenotypically have been characterized by co-expression of CD34 and the kinase insert domain receptor (KDR) [40,41].
Gene_expression (expression) of KDR
16) Confidence 0.57 Published 2010 Journal J Transl Med Section Body Doc Link PMC2862021 Disease Relevance 0 Pain Relevance 0.05
"Angiogenesis switch" in leukemia is documented by increased bone marrow MVD, increased expression of HIF-1, multiple pro-angiogenic factors (VEGF, bFGF, angiopoietin-2), soluble VEGFR, and decreased expression of endogenous angiogenesis inhibitors, such as thrombospondin-1 [50,51].
Gene_expression (expression) of VEGFR in bone marrow associated with leukemia
17) Confidence 0.55 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.52 Pain Relevance 0
Thus, VEGF and VEGFR represent significant anti-cancer therapy targets, which elegantly bypass potential tumor-related treatment barriers [4].
Gene_expression (represent) of VEGFR associated with cancer
18) Confidence 0.55 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.39 Pain Relevance 0
In MPN, VEGF levels were higher compared to controls, wheresas VEGFR-2 levels was reduced in ET but not in PV and PMF [61].


Gene_expression (higher) of VEGFR associated with myeloproliferative disorder, myelodysplastic syndromes and myelofibrosis
19) Confidence 0.55 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.73 Pain Relevance 0
The opposing trend in the biphasic nature of VEGFR2-VEGF165-NRP1 (Fig. 5D) came from the fact that at very low total VEGFR density, quantities of VEGFR2 were so limited that there was an unusual population of VEGF165-NRP1 left at steady state for 2,000 VEGFR/EC (Fig. 5E) with no VEGFR2 to present to.
Neg (no) Gene_expression (present) of VEGFR
20) Confidence 0.55 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox